Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Motif Bio Plc LSE:MTFB London Ordinary Share GB00BVVT4H71 ORD 0.01P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.07 -14.89% 0.40 8,862,005 13:40:44
Bid Price Offer Price High Price Low Price Open Price
0.40 0.44 0.50 0.40 0.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -10.96 -3.92 3
Last Trade Time Trade Type Trade Size Trade Price Currency
13:41:42 O 233,317 0.42856 GBX

Motif Bio (MTFB) Latest News

More Motif Bio News
Motif Bio Takeover Rumours

Motif Bio (MTFB) Discussions and Chat

Motif Bio (MTFB) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
12:41:420.43233,317999.90O
12:40:280.43748,3593,192.50O
12:38:140.4091,627366.05O
12:38:080.36178,009642.65O
12:38:060.4051,941207.50O
View all Motif Bio trades in real-time

Motif Bio (MTFB) Top Chat Posts

DateSubject
02/7/2020
09:20
Motif Bio Daily Update: Motif Bio Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker MTFB. The last closing price for Motif Bio was 0.47p.
Motif Bio Plc has a 4 week average price of 0.40p and a 12 week average price of 0.07p.
The 1 year high share price is 3.30p while the 1 year low share price is currently 0.04p.
There are currently 654,991,023 shares in issue and the average daily traded volume is 7,622,203 shares. The market capitalisation of Motif Bio Plc is £2,619,964.09.
28/6/2020
20:49
elsol: Rapidly, you obviously believe there is a very good probability of a near term excess share price return otherwise you would not be wasting so much of your valuable intellectually challenged energy on so many posts on MTFB in recent weeks....so irrespective of whether the stock price goes up or down a bit in the next week or two is not really important to anyone seriously invested here. The important thing is to have bought into the stock to avoid being locked out at the announcement date of an RTO..and then just wait! Good luck with your strategy if not following the above...I hope you have bought enough shares to enjoy the gross proceeds during the weeks ahead like me and many others on this site.
23/6/2020
11:36
elsol: I agree with you bensdad. An RTO deal of this nature will obviously take some time to complete as its complex in nature (e.g. some items include; negotiation on value splitting and future financing, agreement on final shareholdings/corporate structure, private and corporate tax analysis/management incentive share schemes, detailed legal docs to put together and then once the deal is formalised on paper I guess there could be a need for a formal fairness opinion by accounting firms before the deal can go ahead...so IMHO it was never a dead cert to conclude by now based on the original announcement of the RTO plan with advisors in place - the time clock is still very much running but by no means concluded. In the last 4 weeks, if anything the covid environment has got even better for an RTO with a Covid counter-party not worse so I think the share price volatility represents certain private investors getting frustrated and just selling in fear from all the chatter going on and volatility...just be patient my friends once you are in the stock irrespective of the folks on this site and LSE BB that want your shares!
18/6/2020
09:11
scottdavid70: Would suggest anyone invested here email the various companies to ask why there hasn’t been a TR-1. You can’t drop 48 million shares in a 5 minute period, with zero affect on the share price and tell any of us that those shares haven’t been taken entities. One of which is definitely over the 3% threshold
05/5/2020
14:21
melpan: @bensdad2 - According to 2018 (31/12/18) annual report they had $116m in carried forward losses. Not sure how you would have value them but it wouldn't be at the full corporate tax rate of 18%, maybe 5%-10% at most ? So $5-$10m possible value. An interesting point from the report, the two top guys who run the co (Lumsden and Gold) were paid $1m in salary and $500k in bonuses between them that year. That is a quite a staggering figure for a destruction of £100m of value over 5 yrs. Fine, you can't control what happened re the iclaprim decision in early 2019 so the salary is what it is, but this next bit is interesting... It was sneaked in a footnote that Lumsden was paid that bonus of $264k on 24 Feb 2019 (AFTER the FDA rejection). LTH's would recognise this month, as just 10days earlier on 14/02 they had that rejection from the FDA resulting in an almost 90% share price crash in a few weeks. I'll leave it up to you guys to gauge whether someone should have been paid a bonus at all for that year (on top of an annual $446k salary) for literally failing at the one thing the co was set up to do and losing 90% of shareholder value that same year. And whether post this, if he is still fit and of sufficient integrity to do the same with your new money (albeit in a non exec fashion, Gold is still at the helm though). And another interesting observation, the non execs all seem to be paid too much as a collective (esp Morgan and Bertoldi who each were paid $100k each and resigned later). I would say almost twice as much as I would expect esp given what they presided over. On closer inspection, the board was the proverbial gravy train with each giving the other ludicrous compensation with shareholders' funds (this is excluding the very generous share option plans). PS - Am a LTH since 2015, and am down 95%+ on my inv and will never break even on this anymore (for that to happen the mkt cap needs to be £300m+ after recent diution which is out of the question). I did not average down at the lows as have been through these AIM frauds many times over the last 20yrs. Usually 8/10 times it ends in zero recovery. If you were one of the 2/10 then well done, good on you for taking something back out of the market. There will be no one happier than me if by some miracle this goes onto more than a few pence and the RTO materialises, means I'll get a few grand back from my £25k+ loss. And a tip for any newbies here, always look at the mkt cap of a co rather than share price when looking at these smaller AIM cos as they have usually undergone dilution and/or consolidation at some point (some quite dramatically). So when trying to project a share price target, looking at a historic chart is meaningless, you need to look at historic mkt cap to compare previous highs were etc and to chart its progress. Hope that helps ! Good luck all.
05/5/2020
07:52
bensdad2: The placing is very positive indeed. Even though it is at a discount to the closing price, it is miles above the price at which the shares opened yesterday. Bear in mind that the placing was probably agreed during the course of the last few days, so in effect, the final price which was set was at a large premium to the original share price (ie where it stood before markets opened yesterday). Even when I topped up again at .52p, that was just after 1pm. So it was only after about that point that the placing price would be at a discount. My hunch is therefore that it was set at a premium - almost unheard of. And very positive indeed.
05/5/2020
07:38
bensdad2: I had to bought a number of shares during the rapid movement in the price last week, sold most of them at a decent profit, but was left with some, with a purchase price of 0.27. And I saw the news yesterday early doors and thought very positive, so bought more at .31 and a couple of other points on the way up, last buy at 0.8. I sold most of them in the afternoon to bank profits. One f my best ever trading days, - and normally i am hopeless at trading. I usually manage to buy at the very top of a spike and/or sell far too early. I think this news is very positive, and whilst I expect the share price to move around wildly today, i reckon that it will end up comfortably above my highest buying price (0.8) and probably above its closing price from yesterday.
14/4/2020
09:32
moneymunch: It's not strange reg, it speaks volumes.Gl ;-) In summary, issuers must notify without delay major new developments that may affect their business if the development may lead to a substantial share price movement. Issuers must also notify without delay information concerning a change in financial condition, performance or expectation of performance if the change would be likely to lead to a substantial share price movement. There are exclusions from these notification requirements relating to impending developments and matters in the course of negotiation, such as acquisitions or disposals. There is also a power for the UKLA to grant a dispensation from these requirements where the disclosure to the public of information might prejudice the company's legitimate interests
14/4/2020
07:22
moneymunch: Alas not, but no speeding ticket either on Thursday's stellar rise, and so hopefully good news coming. Gl ;-) In summary, issuers must notify without delay major new developments that may affect their business if the development may lead to a substantial share price movement. Issuers must also notify without delay information concerning a change in financial condition, performance or expectation of performance if the change would be likely to lead to a substantial share price movement. There are exclusions from these notification requirements relating to impending developments and matters in the course of negotiation, such as acquisitions or disposals. There is also a power for the UKLA to grant a dispensation from these requirements where the disclosure to the public of information might prejudice the company's legitimate interests
04/4/2019
20:47
newtothisgame3: #MTFB average analyst price target is $3.5 per share. This means the stock has a potential increase of 83.25% from where the MTFB share price has been trading recently which is between $1.82 and $1.8999 with one of them, even setting their price target at $5. By Peggy Goldman - April 4, 2019 https://twitter.com/smallcappick/status/1113890691476803584
19/1/2019
10:21
barriew: Nothing new but recommendation on Interactive Investor. Motif Bio (MTFB) 39.53p Motif Bio (LSE:MTFB) is developing a new antibiotic called iclaprim. Resistance to existing antibiotics means that it is imperative that new and effective antibiotics are brought onto the market. Iclaprim was originally discovered by Hoffman-La Roche and Motif addressed the reasons it failed to gain FDA approval in 2009. Two phase III trials have been completed in the US. The addressable global market for iclaprim could be worth $2.8 billion. The FDA has accepted the filing of the company's new drug application for iclaprim, relating to the treatment of acute bacterial skin and skin structure infections (ABSSSI). It has been granted priority review with a potential approval date in the first quarter of 2019. Source: TradingView (*) Past performance is not a guide to future performance Commercialisation plans have commenced. It is likely that the US hospital market will be targeted via a contract sales organisation, while in Europe a partner will be sought to help to finance approvals in the region. Motif had $19.8 million of cash at the end of June 2018 and the cash outflows have reduced. More cash is likely to be required in order to launch the product. Motif Bio's multi-billion-dollar best-seller The share price has bounced back in the past few weeks and is not far from its 12-month high – but there should be more to come. The share price is nearly double the 20p a share AIM placing price just short of four years ago. Just over two years ago there was a fundraising at 28p a share as part of the Nasdaq flotation. Barely more than one month ago the share price was below that level. If obtained, FDA approval will increase investor interest on Nasdaq, in particular, and could herald a further share price boost.
Motif Bio share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
MTFB
Motif Bio
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200702 12:59:29